Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is
- to find out the effects of treating patients with two new chemotherapy drugs (bortezomib
and Revlimid™),
- to study how many patients' myeloma responds to treatment on this study, and how many
patients survive after this treatment,
- to learn if a patient's genetic makeup before and after treatment can predict which
patients will respond to bortezomib and Revlimid™, and to learn more about how the body
responds (gene array studies).